Generic Pathway For Biologics Weighed At Hearing

Law360, New York (March 9, 2007, 12:00 AM EST) -- Generic versions of biologic drugs are either a safe and less expensive alternative or could pose a sizable risk to patient safety, depending on whose testimony you believed at a committee hearing in the U.S. Senate on Thursday.

The Senate Health, Education, Labor and Pensions Committee held a hearing Thursday about follow-on biologics as legislators mull bills proposed in both the U.S. House of Representatives and the Senate that would give the U.S. Food and Drug Administration the discretion to decide when it is scientifically appropriate...
To view the full article, register now.